Nyrada, Inc. · ASX:NYR
Nyrada — Investor Presentation (August 2024)
10 slides from Nyrada's investor presentation, Aug 15, 2024
Slide 1: Investor Presentation August 2024
Nyrada Inc. For personal use only Investor Presentation August 2024 Improving Lives, Offering Hope Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board. ASX:NYR NYRADA INC (ASX:NYR) 1
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer This presentation has been prepared by Nyrada Inc (“NYR” or “Company”). It should Although the Company believes that the expectations reflected in the forward-looking For personal use only not be considered as an offer or invitation to subscribe for, or purchase any s
Slide 3: Nyrada's Expertise in Drug Development
Nyrada’s Expertise in Drug Development For personal use only › Drug discovery and development company specialising in novel small molecule therapeutics. › Nyrada’s lead drug candidate, NYR-BI03: › demonstrated strong (preclinical) efficacy protecting the brain from secondary injury. › currently unde
Slide 4: Nyrada Investment Proposition
Nyrada Investment Proposition For personal use only › Brain injury program - significant target market and unmet clinical demand. › First-in-class neuroprotection therapy with novel mode of action. › Pioneering transient receptor potential canonical (TRPC) channel blocking therapies. › Collaboration
Slide 5: Brain Injury Trajectory, Patient Outcomes, Treatment Aims
Brain Injury Trajectory, Patient Outcomes, Treatment Aims Serial reconstruction from MRI Primary Secondary Disability For personal use only 30 mins Injury Injury Level IMPROVED BECAME STAYED DIED WORSE THE SAME 72 hours Hours Days Weeks Months Reduce secondary injury resulting from stroke or TBI Nyr
Slide 6: TRPC 3/6/7 Ion Channels as a Therapeutic Target
TRPC 3/6/7 Ion Channels as a Therapeutic Target › Glutamate release following brain injury results in calcium entry via TRPC ion channels For personal use only › Excessive calcium build-up leads to neuronal cell death › Blocking TRPC 3/6/7 ion channels is neuroprotective against secondary brain inju
Slide 7: Near Term Catalysts
Near Term Catalysts For personal use only NYR-BI03: › 2HCY2024 – Good Laboratory Practice (GLP) safety and tolerability study updates. › 3QCY2024 – Walter Reed (WRAIR) traumatic brain injury/UNSW pre-clinical efficacy study update. › 4QCY2024 – Human Research Ethics Committee application submission.
Slide 8: Brain Injury Program - Indicative Phase I Study Design
Brain Injury Program - Indicative Phase I Study Design OBJECTIVES To assess the safety, tolerability, and pharmacokinetics of NYR-BI03 For personal use only DESIGN • Randomised, double-blind placebo – PARTICIPANTS controlled, dose escalation design • Male and female healthy volunteers • 5 cohorts; 8
Slide 9: Contact Nyrada
Contact Nyrada For personal use only Contact Nyrada Inc: › Email: info@nyrada.com › Web: www.nyrada.com › Subscribe: www.nyrada.com/site/contact/email-alerts › Phone: +61 2 9498 3390 NYRADA INC (ASX:NYR) 9
Slide 10: Brain Injury Solution
For personal use only Brain Injury Solution Animation Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board. @nyrada_inc @nyrada_inc ASX:NYR info@nyrada.com www.nyrada.com NYRADA INC (ASX:NYR) 10